We Give Shareholders a Voice

XBiotech Inc. Information Request Form

Levi & Korsinsky, LLP announces the filing of a class action lawsuit in the United States District Court for the Western District of Texas on behalf of shareholders of XBiotech Inc. (Nasdaq: XBIT) who purchased shares between April 15, 2015 and November 23, 2015.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome. If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving XBiotech Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other XBiotech shareholders.

Sincerely,

Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear